Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Short Interest Update

17 Apr 2026, 18:23 by Amy Steele · The Cerbat Gem

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) saw a significant increase in short interest in March. As of March 31st, there was short interest totaling 18,580,923 shares, an increase of 26.5% from the March 15th total of 14,693,507 shares. Currently, 22.6% of the shares of the stock are sold short. Based on an average daily volume of 6,423,862 shares, the days-to-cover ratio is currently 2.9 days.

Rocket Pharmaceuticals Trading Up 0.3%

NASDAQ RCKT traded up $0.01 on Friday, reaching $3.91. The company had a trading volume of 2,026,687 shares, compared to its average volume of 3,220,092. The stock’s 50 day moving average is $4.05 and its 200-day moving average is $3.67. The stock has a market cap of $426.67 million, a price-to-earnings ratio of -1.95 and a beta of 0.57. The company has a quick ratio of 6.38, a current ratio of 6.38 and a debt-to-equity ratio of 0.07. Rocket Pharmaceuticals has a 52 week low of $2.19 and a 52 week high of $8.26.

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.04. During the same period in the prior year, the company posted ($0.62) earnings per share. Equities analysts predict that Rocket Pharmaceuticals will post -2.83 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on RCKT. Cantor Fitzgerald boosted their target price on Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Bank of America boosted their target price on Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, March 30th. Morgan Stanley set a $5.00 target price on Rocket Pharmaceuticals in a research report on Thursday, January 8th. The Goldman Sachs Group boosted their target price on Rocket Pharmaceuticals to $3.00 and gave the stock a “sell” rating in a research report on Monday, March 2nd. Finally, Lifesci Capital upgraded Rocket Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $13.86.

View Our Latest Report on Rocket Pharmaceuticals

Insiders Place Their Bets

In other news, CEO Gaurav Shah sold 12,279 shares of the business’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the sale, the chief executive officer owned 1,052,045 shares in the company, valued at $3,482,268.95. The trade was a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Martin Wilson sold 12,253 shares of the business’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $3.31, for a total value of $40,557.43. Following the sale, the general counsel owned 683,376 shares of the company’s stock, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 29,415 shares of company stock worth $97,398. Insiders own 24.76% of the company’s stock.

Institutional Investors Weigh In On Rocket Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Rocket Pharmaceuticals by 12.6% in the third quarter. Vanguard Group Inc. now owns 6,892,204 shares of the biotechnology company’s stock valued at $22,469,000 after purchasing an additional 769,743 shares during the last quarter. MPM Bioimpact LLC increased its holdings in shares of Rocket Pharmaceuticals by 141.2% in the second quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company’s stock worth $9,563,000 after acquiring an additional 2,284,816 shares in the last quarter. Millennium Management LLC raised its position in shares of Rocket Pharmaceuticals by 52.0% during the third quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company’s stock worth $11,639,000 after purchasing an additional 1,221,554 shares during the period. Monaco Asset Management SAM lifted its holdings in shares of Rocket Pharmaceuticals by 3.3% during the 4th quarter. Monaco Asset Management SAM now owns 2,987,296 shares of the biotechnology company’s stock valued at $10,485,000 after purchasing an additional 95,035 shares in the last quarter. Finally, Newtyn Management LLC lifted its holdings in shares of Rocket Pharmaceuticals by 25.1% during the 3rd quarter. Newtyn Management LLC now owns 2,502,863 shares of the biotechnology company’s stock valued at $8,159,000 after purchasing an additional 502,863 shares in the last quarter. Institutional investors own 98.39% of the company’s stock.

About Rocket Pharmaceuticals

(Get Free Report)

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.